# A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

> **NCT03486899** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 197 (actual)

## Conditions studied

- Liver Fibrosis
- Nonalcoholic Fatty Liver Disease (NAFLD)
- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** BMS-986036
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03486899
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-19
- **Primary completion:** 2020-09-14
- **Final completion:** 2021-08-17
- **Target enrollment:** 197 (ACTUAL)
- **Last updated:** 2022-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03486899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03486899, "A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03486899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*